Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value

International Journal of Cancer

Volumn 79, Issue 5, 1998, Pages 494-501

  Levesque, Michael A ^a,b   D'Costa, Mario ^b,c   Spratt, Ernest H ^b,c   Yaman, Mohammad M ^b   Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RISK; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; QUANTITATIVE ASSAY; STATISTICAL ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROIMMUNOASSAY; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; SMOKING; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031691792     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981023)79:5<494::AID-IJC9>3.0.CO;2-W     Document Type: Article

References (36)

1. BEAHRS, O.H., HENSON, D.E., HUTTER, R.V.P. and KENNEDY, B.J. Manual for staging of cancer (3rd ed.), pp. 115-122. J.B. Lippincott, Philadelphia (1992).
2. BENNETT, W.P. and 15 OTHERS, p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res., 53, 4817-4822 (1993).
3. BRAUCH, H., JOHNSON, B., HOVIS, J., YANO, T., GAZDAR, A., PETTENGILL, O., GRAZIANO, S., SORENSON, G., POIESZ, B., MINNA, J., LINEMAN, M. and ZBAR, B., Molecular analysis of the short arm of chromosome 3 in small-cell and non-small cell carcinoma of the lung. N. Engl. J. Med., 317, 1109-1113 (1987).
4. CASEY, G., LOPEZ, M.E., RAMOS, J.C., PLUMMER, S.J., ARBOLEDA, M.J., SHAUGHNESSY, M., KARLAN, B. and SLAMON, D.J., DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene, 13, 1971-1981 (1996).
5. CHARPIN, C., GARCIA, S., BOUVIER, C., ANDRAC, L., DEVICTOR, B., LAVAUT, M.N., ALLASIA, C., BONNIER, P. and PIANA, L., Quantitative immunocytochemical assays on frozen sections of p53; correlation to the follow-up of patients with breast carcinomas. Amer. J. Clin. Pathol., 106, 640-646 (1996).
6. CHIBA, I. and 14 OTHERS, Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene, 5, 1603-1610 (1990).
7. CHRISTOPOULOS, T.K. and DIAMANDIS, E.P., Enzymatically-amplified time-resolved fluorescence immunoassay with terbium chelates. Anal. Chem., 64, 243-346 (1992).
8. FONTANINI, G., VIGNATI, S., BIGINI, D., MERLO, G.R., RIBECCHINI, A., ANGELETTI, C.A., BASOLO, F., PINGITORE, R. and BEVILACQUA, G., Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J. Pathol., 174, 23-31 (1994).
9. FUKUYAMA, Y, MITSUDOMI, T., ISHIDA, T., AKAZAWA, K. and SUGIMACHI, K., K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small cell lung cancer. Brit. J. Cancer, 75, 1125-1130 (1997).
10. HARPOLE, D.H., HERNDON, J.E., WOLFE, W.G., IGLEHART, J.D. and MARKS, J.R., A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res., 55, 51-56 (1995).
11. HASSAPOGLIDOU, S., DIAMANDIS, E.P. and SUTHERLAND, D.J.A., Quantification of p53 protein in tumour cell lines, breast tissues extracts and serum with time-resolved immunofluorometry. Oncogene, 8, 1501-1509 (1993).
12. KASTAN, M.B., ZHAN, Q., EL-DEIRY, W.S., CARRIER, F., JACKS, T., WALSH, W.V., PLUNKETT, B.S., VOGELSTEIN, B. and FORNACE, A.J., A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71, 587-597 (1992).
13. KISHIMOTO, Y., MURAKAMI, Y., SHIRAISHI, M., HAYASHI, K. and SEKIYA, T., Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res., 52, 4799-4804 (1992).
14. LEE, J.-S., YOON, A., KALAPURAKAL, S.K., RO, J.Y., LEE, J.J., TU, N., HITTLEMAN, W.N. and HONG, W.K., Expression of p53 oncoprotein in non-small cell lung cancer: a favorable prognostic factor. J. clin. Oncol., 13, 1893-1903 (1995).
15. LEVESQUE, M.A., D'COSTA, M., ANGELOPOULOU, K. and DIAMANDIS, E.P., Time-resolved immunofluorometric assay of p53 protein. Clin. Chem., 41, 1720-1729 (1995).
16. LEVESQVE, M.A., KATSAROS, D., YU, H., GIAI, M., GENTA, F., ROAGNA, R., PONZONE, R., MASSOBRIO, M., SISMONDI, P. and DIAMANDIS, E.P., Immunofluorometrically-determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. Int. J. Cancer (Pred. Oncol.) 79, 147-152 (1998).
17. LEVESQUE, M.A., TADROSS, L., DIAMANDIS, E.P. and D'COSTA, M., Comparison of immunofluorometry and immunohistochemistry for the detection of p53 protein in lung cancer specimens. Amer. J. clin. Pathol., 107, 308-316 (1997).
18. LOWE, S.W., SCHMITT, E.M., SMITH, S.W., OSBORNE, B.A. and JACKS, T., p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362, 847-849 (1993).
19. LUO, J.-C., ZEHAB, R., ANTTILA, S., RIDANPAA, M., HUSGAFVEL-PURSIAINEN, K., VAINIO, H., CARNEY, W., DEVIVO, I., MILUNG, C. and BRANDT-RAUF, P.W., Detection of serum p53 protein in lung cancer patients. J. occup. Med., 36, 155-160 (1994).
20. MAHCHETTI, A., BLITTITA, F., MERLO, G., DIELLA, F., PELLEGRINI, S., PEPE, S., MACCHIARINI, P., CHELLA, A., ANGELETTI, C.A., CALLAHAN, R., BISTOCCHI, M. and SQUARTINI, F., p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res., 53, 2846-2851 (1993).
21. MCLAREN, R., KUZU, I., DUNNILL, M., HARRIS, A., LANE, D. and GATTER, K.C., The relationship of p53 immunostaining to survival in carcinoma of the lung. Brit. J. Cancer, 66, 735-738 (1992).
22. MITSUDOMI, T., OYAMA, T., KUSANO, T., OSAKI, T., NAKANISHI, R. and SHIRAKUSA, T., Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J. nat. Cancer Inst., 85, 2018-2023 (1993).
23. MOUNTAIN, C.F., A new international staging system for lung cancer. Chest, 89, 225-233 (1986).
24. NISHIO, M., KOSHIKAWA, T., KUROISHI, T., SUYAMA, M., UCHIDA, K., TAKAGI, Y., WASHIMI, O., SUGIURA, T., ARIYOSHI, Y., TAKAHASHI, T., UEDA, R. and TAKAHASHI, T., Prognostic significance of abnormal p53 accumulation in primary, resected non-small cell lung cancers. J. clin. Oncol., 14, 497-502 (1996).
25. PAPPOT, H., FRANCIS, D., BRÜNNER, N., GRØNDAHL-HANSEN, J. and ØSTERLIND, K., p53 protein in non-small cell lung cancer as quantified by enzyme-linked immunosorbent assay: relation to prognosis. Clin. Cancer Res., 2, 155-160 (1996).
26. PASSLICK, B., IZBICKI, J., HÄUSSINGER, K., THETTER, O. and PANTEL, K., Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., 109, 1205-1211 (1995).
27. QUINLAN, D.C., DAVIDSON, A.G., SUMMERS, C.L., WARDEN, H.E. and DOSHI, H.M., Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res., 52, 4828-4831 (1992).
28. RUSCH, V., KLIMSTRA, D., VENKATRAMAN, E., OLIVER, J., MARTINI, N., GRALLA, R., KRIS, M. and DMITROVSKY, E., Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res., 55, 5038-5042 (1995).
29. SOZZI, G., MIOZZO, M., DONGHI, R., PILOTTI, S., CARIANI, C.T., PASTORINO, U., DELLA PORTA, G. and PIEROTTI, M.A., Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res., 52, 6079-6082 (1992).
30. SOZZI, G., MIOZZO, M., PASTORINO, U., PILOTTI, S., DONGHI, R., GIAROLA, M., DE GREGORIO, L., MANENTI, G., RADICE, P., MINOLETTI, F. and DELLA PORTA, G., Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res., 55, 135-140 (1995).
31. SUZUKI, H., TAKAHASHI, T., KUROISHI, T., SUYAMA, M., ARIYOSHI, Y., TAKAHASHI, T. and UEDA, R., p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res., 52, 734-736 (1992).
32. THOMAS, M.D., MCINTOSH, G.G., ANDERSON, J.J., MCKENNA, D.M., JOHNSTONE, R., LENNARD, T.W.J., HORNE, C.H.W. and ANGUS, B., A novel quantitative immunoassay system for p53 using antibodies selected for optimum designation of p53 status. J. clin. Pathol., 50, 143-147 (1997).
33. TOP, B., MOOI, W.J., KLAVER, S.G., BOERRIGTER, L., WISMAN, P., ELBERS, H.R.J., VISSER, S. and RODENHUIS, S., Comparative analysis of p53 gene mutations and protein accumulation in human non-small cell lung cancer. Int. J. Cancer (Pred. Oncol.), 64, 83-91 (1995).
34. VOJTĚŠEK, B., BÁRTEK, J., MIDGELY, C.A. and LANE, D.P., An immunochemical analysis of the human nuclear phosphoprotein p53. J. Immunol. Methods. 151, 237-244 (1992).
35. WORLD HEALTH ORGANIZATION, Histological typing of lung tumors. Amer. J. clin. Pathol., 11, 123-136 (1982).
36. WYNFORD-THOMAS, D., p53 in tumour pathology: can we trust immunocytochemistry? J. Pathol., 166, 329-330 (1992).